Listen
NEXOBRID (concentrate of proteolytic enzymes enriched in bromelain), enzymes
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Jan 08 2016
Reason for request
Inclusion
Insufficient actual benefit in the treatment of eschars associated with deep partial- and full-thickness thermal burns
- NEXOBRID has a Marketing Authorisation for removal of eschar in adults with deep partial- and full-thickness thermal burns.
- Given the absence of demonstrated clinical benefit and the increase in adverse effects by comparison with the standard treatment, the actual benefit of NEXOBRID is insufficient to justify its reimbursement.
Clinical Benefit
| Insufficient |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
